Randomized comparative clinical study on alpha 1 receptor blockers silodosin and urapidil for female lower urinary tract symptoms
- Conditions
- ower urinary tract symptom
- Registration Number
- JPRN-UMIN000011755
- Lead Sponsor
- Kinki University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 100
Not provided
Patient with serious comorbid heart disease (such as ischemic heart disease, serious arrythmia, myocardial disease, and myocarditis) Patient with serious comorbid liver disease or total bilirubin level 3 mg/dL and over or AST(GOT) or ALT(GPT) 2.5 times and over the upper limit of the reference range Patient with serious comorbid kidney disease (such as nephrotic syndrome, acute kidney disease, acute nephritis, and chronic renal failure) or serum creatinine level are 1.5mg/dL and over Patient with serious hypotension Woman who is pregnant, nursing, wishes to become pregnant during the study period, or cannot follow physician's instructions regarding contraception Patient to whom urapidil was administered within 2 weeks of the initiation of the study Patient to whom another kind of alpha receptor blocker has been administered Patient for whom change or initiation of drug administration or change in dosage affecting urinary function was made within one month before initiation of the study Patient who have undergone radiotherapy for the pelvis Patient with active urinary tract infection Patient whose symptoms are considered to aggravate rapidly (such as urinary retention) due to cessation of urapidil Others judged to be unsuited as subjects according to the Principal Investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method